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In 1965, Blumberg, Alter and Visnich described a ‘new’ antigen in
sera from patients with leukaemia, and in 1970, Prince and
colleagues went on to show that this SH (serum hepatitis) antigen
was associated with chronic hepatitis. A decade later, Beasley et al
(1981), working in Taiwan, showed that the risk of developing
liver cancer among men positive for this marker of persistent
hepatitis B virus (HBV) infection was approximately 200 times
greater than that among men without the marker. Although this
relative risk fell with further follow-up to around 100 (Beasley and
Hwang, 1991), the very strong association between the hepatitis B
carrier state and the risk of hepatocellular cancer has been repli-
cated in multiple case–control and cohort studies in various parts
of the world (IARC, 1994). The strength and consistency of these
findings, together with evidence of biological plausibility gained
from animal models, led the International Agency for Research on
Cancer to conclude that there is sufficient evidence for the carcino-
genicity of chronic infection with HBV in humans (IARC, 1994).
It has been estimated that at least 60% of cases of primary liver
cancer worldwide and 67% in developing countries are attribut-
able to persistent infection with HBV (Pisani et al, 1997). The
burden of mortality due to chronic hepatitis and cirrhosis that is
attributable to hepatitis B infection is much less clear due to a
paucity of relevant studies but is likely to exceed that due to liver
cancer. It has been estimated that around 40% of hepatitis B
carriers will die as a result of the infection. Since approximately
20% of adults in China and sub-Saharan Africa are carriers, this
signifies a major global public health problem.
Only a minority of those infected with HBV become persis-
tently infected, the major determinant being the age at first expo-
sure to the virus (Edmunds et al, 1993). In China, where infection
occurring around the time of birth from an infectious mother is
common, about 40% of carriers are infected perinatally (IARC,
1994). There, about 90% of children born to carrier mothers are
infected and perinatal infection is associated with about a 90% risk
of becoming a carrier (Beasley et al, 1977; Mitusda et al, 1989). In
many other parts of Asia and in sub-Saharan Africa, infection is
most common in childhood. In The Gambia, for example, between
35% and 70% of children were found to have been infected by the
age of 5 years (Whittle et al, 1990). Although the prevalence of
infectious mothers in such populations is substantially lower than
in China, the rates of chronic infection in the population are still
high, as the probability of becoming a carrier following infection
in early childhood is around 20–30%. In contrast, the risk of
becoming a carrier following infection in adolescence or adult life
is less than 10%. This pattern makes the options for prevention
clear. Either primary prevention of persistent infection must be
undertaken early in life (particularly very early in life in China), or
secondary prevention measures must be directed at reducing the
risk associated with carriage later in life.
Progress on these two possible intervention strategies has been
unequal. Secondary prevention by modification of carriage can
now be made by anti-viral therapy but is currently expensive and
its long-term effectiveness has yet to be demonstrated. The high
cost is a particularly important issue since the vast majority of
carriers in the world live in Asia and Africa, where resources are
very limited. Alcohol avoidance is likely to reduce the risks asso-
ciated with carriage but this is a difficult intervention to imple-
ment. The likely role of dietary aflatoxin has become clearer in
recent years. Cohort studies in which stored samples have been
analysed for biomarkers of aflatoxin exposure on a case–control
basis indicate that aflatoxin exposure increases the risk of liver
cancer by around twofold (Ross et al, 1992). However, because the
risk appears to be multiplicative, the impact of such exposure
among hepatitis B carriers, who are at high risk of liver cancer,
may be substantial. This has led to more recent focus on the possi-
bility of benefiting carriers by reducing their aflatoxin exposure.
Oltipraz, an anti-schistosomal drug, induces aflatoxin metabo-
lizing enzymes and has been shown to inhibit aflatoxin-induced
hepatocarcinogenesis in animal models (Kensler et al, 1999).
Whilst some trials of this chemotherapeutic agent in humans have
been conducted (Wang et al, 1999), this does not represent a real-
istic option in the affected resource-poor countries. A more attrac-
tive agricultural approach is to reduce contamination of locally
consumed foodstuff; however, field trials are needed using human
biomarker exposure as the end point to assess their effectiveness,
and ultimately intervention studies to assess whether simple, tech-
nologically appropriate interventions can reduce the incidence of
hepatocellular carcinoma.
In contrast, great strides have been made in primary prevention.
Hepatitis B vaccine has been available since 1980. Initial studies
in the USA showed its effectiveness in preventing infection and
acute hepatitis. More importantly, studies in China, Taiwan and
West Africa demonstrated that vaccination at birth or in early
childhood prevented the chronic carrier state: the efficacy in China
was between 70% and 85% (Sun et al, 1986, 1991) but in Africa
where perinatal transmission is less common it was over 90%
(Fortuin et al, 1993). Recently, this protection has been shown to
persist up to 9 years of age (Viviani et al, 1999), which is more
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Correspondence to: PG Smithimportant since it covers the period of life when the risk of
carriage if infected is high. Thus, even if vaccine-induced immu-
nity wanes later in life, there is good reason to suppose that
carriage will have been prevented in a substantial proportion of
vaccinated individuals, even without any booster vaccination.
Direct evidence of the protective effect of hepatitis B vaccination
against liver cancer comes from a study in Taiwan where all new-
borns have been vaccinated since the mid 1980s. The rate of liver
cancer among children aged 6–9 years in the vaccinated cohort
was 1.3 million–1 year–1 compared to a rate of 5.2 million–1 year–1
in the preceding unvaccinated cohort (Chang et al, 1997). Whilst
these data have accumulated the price of vaccine has fallen
dramatically from around $40 per dose in the early 1980s to less
than $1 per dose now. At this price it has been estimated that, in
West Africa, the prevention of one carrier of the virus costs
between $20 and $30, and the prevention of a case of primary liver
cancer (which is uniformly fatal) only $130 (Hall et al, 1993).
Since the target for vaccination is infants this is a once and for
all lifetime cost for each individual in terms of prevention of HBV
carriage and liver cancer. The corresponding cost in measles
vaccination is around $40 per death prevented, and that of
preventing a diarrhoeal death by improved water supply and
sanitation is estimated at $1200 per death prevented.
This evidence led the WHO to recommend universal hepatitis B
vaccination for all countries of the world either in infancy (where
childhood infection is common) or in pre-adolescence (where
adolescent or adult infection is the main problem). Currently,
although more than 100 countries have instituted this policy, there
is a marked geographical disparity. The African continent lags far
behind the rest of the world, despite the public health importance
of liver cancer there, with only two countries having integrated
hepatitis B vaccine into their national childhood vaccine
programmes. The limited cancer registry data in sub-Saharan
Africa suggests that this is the commonest cancer in men and the
second commonest in women (Bah et al, 1990). It is estimated that
some 10% of adult West Africans will die prematurely as a result
of infection with the virus.
Most causes of adult mortality have proved intractable to simple
preventive interventions. Many of the potential preventive inter-
ventions require difficult to implement changes in lifestyle. Given
the importance of the long-term sequelae of hepatitis B in Africa
and other developing regions of the world, the prevention of the
hepatitis B carrier state by the introduction of hepatitis B vaccina-
tion into routine universal childhood vaccination programmes is
probably one of the simplest and most cost-effective means of
reducing levels of adult mortality. Indeed, it is difficult to think of
any other intervention which costs less than $3 per individual and
which could have such a significant impact on adult mortality in
developing countries. It is true that the major benefit would not be
felt for several decades after such vaccination started but it would
seem very short-sighted not to give this preventive measure high
priority now. Most welcome, therefore, is the recent announce-
ment that the expansion of programmes of hepatitis B vaccination
in developing countries is to be given priority by the Programme
for Appropriate Technology in Health (PATH) with substantial
financial support from the Bill and Melinda Gates Children’s
Vaccine Program.
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